CA3147588A1 - Methods useful in treating cancers harboring a kras or hras mutation or amplification - Google Patents

Methods useful in treating cancers harboring a kras or hras mutation or amplification Download PDF

Info

Publication number
CA3147588A1
CA3147588A1 CA3147588A CA3147588A CA3147588A1 CA 3147588 A1 CA3147588 A1 CA 3147588A1 CA 3147588 A CA3147588 A CA 3147588A CA 3147588 A CA3147588 A CA 3147588A CA 3147588 A1 CA3147588 A1 CA 3147588A1
Authority
CA
Canada
Prior art keywords
cancer
compound
subject
administering
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3147588A
Other languages
English (en)
French (fr)
Inventor
Daniel Heller
Christopher HOROSZKO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of CA3147588A1 publication Critical patent/CA3147588A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3147588A 2019-07-15 2020-07-15 Methods useful in treating cancers harboring a kras or hras mutation or amplification Pending CA3147588A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962874474P 2019-07-15 2019-07-15
US62/874,474 2019-07-15
PCT/US2020/042162 WO2021011674A1 (en) 2019-07-15 2020-07-15 Methods useful in treating cancers harboring a kras or hras mutation or amplification

Publications (1)

Publication Number Publication Date
CA3147588A1 true CA3147588A1 (en) 2021-01-21

Family

ID=74211326

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3147588A Pending CA3147588A1 (en) 2019-07-15 2020-07-15 Methods useful in treating cancers harboring a kras or hras mutation or amplification

Country Status (7)

Country Link
US (1) US20220257599A1 (https=)
EP (1) EP3999049A4 (https=)
JP (1) JP2022540921A (https=)
CN (1) CN114364377A (https=)
AU (1) AU2020315388A1 (https=)
CA (1) CA3147588A1 (https=)
WO (1) WO2021011674A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102679204B1 (ko) * 2021-02-10 2024-06-27 한국생명공학연구원 GPX4 저해제 및 Lp-PLA2 저해제를 포함하는 암 예방 또는 치료용 조성물
WO2024077085A1 (en) * 2022-10-07 2024-04-11 Memorial Sloan-Kettering Cancer Center Targeting phospholipase a2 (pla2) in cancer
US12314787B2 (en) 2023-04-27 2025-05-27 Hewlett Packard Enterprise Development Lp Serving application programming interface calls directed to hierarchical data format files stored in fabric-attached memories

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150017671A1 (en) * 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
CA2830958A1 (en) * 2011-04-06 2012-10-11 The Scripps Research Institute N1- and n2-carbamoyl-1,2,3-triazole serine hydrolase inhibitors and methods
CN102166364A (zh) * 2011-04-14 2011-08-31 江南大学 用于治疗卵巢癌的钙离子非依赖性磷脂酶a2的抑制剂
KR20160117596A (ko) * 2014-02-07 2016-10-10 오스펙스 파마슈티칼스, 인코포레이티드 신규 제약 제제
AU2017329090B9 (en) * 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
US20190142835A1 (en) * 2017-11-14 2019-05-16 Oregon Health & Science University Inhibition of autophagy using phospholipase a2 inhibitors

Also Published As

Publication number Publication date
WO2021011674A1 (en) 2021-01-21
EP3999049A1 (en) 2022-05-25
AU2020315388A1 (en) 2022-02-17
JP2022540921A (ja) 2022-09-20
CN114364377A (zh) 2022-04-15
EP3999049A4 (en) 2023-07-26
US20220257599A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
Singh et al. Enhancement of the gut barrier integrity by a microbial metabolite through the Nrf2 pathway
Zhang et al. Adipocyte-derived lipids mediate melanoma progression via FATP proteins
Pathak et al. Dichotomous role of the human mitochondrial Na+/Ca2+/Li+ exchanger NCLX in colorectal cancer growth and metastasis
Rysman et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation
EP2965763B1 (en) Anti-aging agents
US20220257599A1 (en) Methods useful in treating cancers harboring a kras or hras mutation or amplification
KR101928543B1 (ko) 니클로사마이드를 함유하는 Axin-GSK3 단백질 결합 관련 질환 치료용 약학조성물
Takahashi-Yanaga et al. DIF-1 inhibits tumor growth in vivo reducing phosphorylation of GSK-3β and expressions of cyclin D1 and TCF7L2 in cancer model mice
CN106715436A (zh) 用于癌症治疗的小分子抑制剂
KR102824773B1 (ko) 대사성 질환 및/또는 그것의 임상적 상태를 억제 및/또는 치료하기 위한 조성물 및 방법
Wang et al. Oncogenic RAS induces a distinctive form of non-canonical autophagy mediated by the P38-ULK1-PI4KB axis
Qin et al. CCT251545 enhances drug delivery and potentiates chemotherapy in multidrug-resistant cancers by Rac1-mediated macropinocytosis
KR102000425B1 (ko) 글루코코르티코이드계 화합물을 포함하는 비소세포성 폐암 치료용 약학 조성물
Kang et al. Rebamipide attenuates Helicobacter pylori CagA-induced self-renewal capacity via modulation of β-catenin signaling axis in gastric cancer-initiating cells
JP2021532158A (ja) 転移性癌および化学療法抵抗性癌の治療のためのテトラヒドロキノリノ誘導体
WO2016076359A1 (ja) イベルメクチン又はミルベマイシンｄを有効成分として含む抗癌剤
John et al. Diverse sensitivity of cells representing various stages of colon carcinogenesis to increased extracellular zinc: implications for zinc chemoprevention
US20220288130A1 (en) Compositions and methods for diagnosis and treatment of metabolic diseases and disorders
Peng et al. mTOR inhibition sensitizes human hepatocellular carcinoma cells to resminostat
Zhao et al. Induction of apoptosis by 5, 7-dihydroxy-8-nitrochrysin in breast cancer cells: the role of reactive oxygen species and Akt
Wei et al. Study on the mechanism of solasonine inhibiting the proliferation of oral squamous cell carcinoma based on lipidomics
Fontana Linking metabolic reprogramming to chemo-immuno-resistance: identifying new predictive biomarkers and druggable targets moving from OMIC techniques to single cell analysis
Yang et al. PLA2G16 deficiency enhances oxaliplatin sensitivity in colorectal cancer
US20240000977A1 (en) Methods and kits for diagnosing and treating cancers
Paoli OPA1-driven cristae remodeling promotes pancreatic cancer progression

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220923